La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shanghai GenTech Bilan de santé

Santé financière contrôle des critères 5/6

Shanghai GenTech possède un total de capitaux propres de CN¥3.1B et une dette totale de CN¥879.2M, ce qui porte son ratio d'endettement à 27.9%. Son actif total et son passif total sont CN¥8.7B et de CN¥5.5B. L'EBIT de Shanghai GenTech est CN¥404.3M ce qui fait que son ratio de couverture des intérêts 489.4. Elle dispose de liquidités et de placements à court terme de CN¥671.2M.

Informations clés

27.9%

Ratio d'endettement

CN¥879.19m

Dette

Ratio de couverture des intérêts	489.4x
Argent liquide	CN¥671.24m
Fonds propres	CN¥3.15b
Total du passif	CN¥5.52b
Total des actifs	CN¥8.66b

Mises à jour récentes de la santé financière

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Jul 29

Recent updates

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Mar 03

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 688596 ( CN¥6.9B ) dépassent ses passifs à court terme ( CN¥5.1B ).

Passif à long terme: Les actifs à court terme de 688596 ( CN¥6.9B ) dépassent ses passifs à long terme ( CN¥420.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 688596 ( 6.6% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 688596 a été réduit de 37.5% à 27.9% au cours des 5 dernières années.

Couverture de la dette: La dette de 688596 n'est pas bien couverte par le flux de trésorerie opérationnel ( 3.9% ).

Couverture des intérêts: Les paiements d'intérêts de 688596 sur sa dette sont bien couverts par l'EBIT ( 489.4 x couverture).

Shanghai GenTech Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Recent updates

Investor sentiment deteriorates as stock falls 16%

Does Shanghai GenTech (SHSE:688596) Have A Healthy Balance Sheet?

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

Shanghai GenTech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sentiment Still Eluding Shanghai GenTech Co., Ltd. (SHSE:688596)

Price target decreased by 9.8% to CN¥46.00

Do Shanghai GenTech's (SHSE:688596) Earnings Warrant Your Attention?

New minor risk - Dividend sustainability

Shanghai GenTech's (SHSE:688596) Profits May Not Reveal Underlying Issues

First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.04 in 1Q 2023)

Shanghai GenTech Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Shanghai GenTech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Returns On Capital At Shanghai GenTech (SHSE:688596) Have Stalled

A Piece Of The Puzzle Missing From Shanghai GenTech Co., Ltd.'s (SHSE:688596) 26% Share Price Climb

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 50 million worth of its shares.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.33 in 3Q 2022)

Price target decreased by 9.4% to CN¥52.00

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.19 in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 1Q 2022)

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 12% to CN¥50.50

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.21 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanghai GenTech Co., Ltd. announced that it expects to receive CNY 300 million in funding

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai GenTech Co., Ltd. (SHSE:688596) announces an Equity Buyback for CNY 120 million worth of its shares.

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.17 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.07 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.48 (vs CN¥0.45 in FY 2019)

New 90-day low: CN¥15.90

Investor sentiment deteriorated over the past week

New 90-day low: CN¥18.86

New 90-day low: CN¥20.75

Shanghai GenTech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines